According to bombshell allegations from a group of highly respected experts, the medical world is rife with research fraud. Up to one in five studies published each year could be invented or plagiarised.
By Alfred I. Neugut | June 03, 2021
We discussed in last week’s article the potential use of autologous bone marrow transplantation (BMT) for giving dramatically higher doses of chemotherapy than would normally be possible with conventional methods. This has been successfully utilized for hematologic malignancies, like leukemia. For most solid tumors, there is not good evidence to suggest that increasing the chemotherapy dose would matter, or improve survival.
Theoretically, one would want to target an aggressive treatment like autologous BMT to a tumor where there was evidence from prior research that suggested that more intensive chemotherapy could be more successful. Among the solid tumors, perhaps the best-known example is breast cancer, which is known to be more responsive to dose-dense, i.e., more intensive chemotherapy. Indeed, most women with localized breast cancer are treated with dose-dense chemotherapy as the preferred approach, and thus they do experie